Herantis Pharma Plc Company release 14 March 2022 at 12:20 p.m. EET
The Shareholders' Nomination Committee presents the following proposals to the Annual General Meeting to be held on 21 April 2022. The proposals will be included in the notice to the Annual General Meeting to be published at a later date.
Proposal on the number of the members and election of the members of the Board of Directors
The Shareholders' Nomination Committee proposes that the number of members of the Board of Directors shall be six (6).
The Shareholders' Nomination Committee further proposes that all current members of the Board of Directors, i.e. Timo Veromaa, Mats Thorén, Frans Wuite, James Phillips, Aki Prihti, and Hilde Furberg shall be re-elected as members of the Board of Directors.
Proposal on the remuneration of the members of the Board of Directors and reimbursement of travel expenses
The Shareholders' Nomination Committee proposes that the remuneration of the Board of Directors shall be as follows:
- The remuneration payable to the members of the Board of Directors shall be EUR 18,000 annually for each member of the Board except for the Chairman of the Board who shall be paid EUR 30,000 annually. The remuneration proposed above remains unchanged from the previous year. However, the Board of Directors will no longer elect a Vice Chairman of the Board from among its members, and thus the previously paid annual remuneration of EUR 24,000 related to the position will no longer be paid.
- The Chairman of the Audit Committee shall receive a fixed annual fee of EUR 8,000 and each member of the Audit Committee a fixed annual fee of EUR 4,000.
- The Chairman of the Remuneration Committee shall receive a fixed annual fee of EUR 4,000 and each member of the Remuneration Committee a fixed annual fee of EUR 2,000.
- Board members are also reimbursed reasonable travel expenses related to the duties of the Board of Directors.
Composition of the Shareholders' Nomination Committee
The Shareholders' Nomination Committee was established by Herantis Pharma's Annual General Meeting on 8 April 2020. In accordance with the Charter of the Shareholders' Nomination Committee, the Committee consists of four members. Three members represent the Company's largest shareholders who, on the last business day of September preceding the next Annual General Meeting, hold the largest number of votes calculated of all shares in the Company. The Chairman of Herantis Pharma’s Board of Directors serves as the fourth member of the Nomination Committee. The largest shareholders of the Company on the last business day of September are determined on the basis of the shareholders' register of the Company held by Euroclear Finland Ltd and Euroclear Sweden AB.
In November 2021, the following members were appointed to Herantis Pharma's Shareholders' Nomination Committee:
- Marko Berg, Helsinki University Funds (Chairman);
- Pia Gisgård, Swedbank Robur Fonder AB;
- Aki Prihti, Inveni Life Sciences Fund I Ky; and
- Timo Veromaa, the Chairman of Herantis Pharma's Board of Directors.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis focuses on disease modifying, CDNF-based therapies for Parkinson’s disease that aim to restore proteostasis, body’s natural neuronal protective mechanism. A failure in proteostasis results in pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated in the development of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease. CDNF is a protein that occurs naturally in the body. Its role is to protect neurons by balancing proteostasis, thereby preventing and counteracting disease generating mechanisms.
Herantis' development focus is on the CDNF-based; HER-096 (a synthetic peptide). HER-096 has demonstrated to have a multimodal mechanism of action mimicking CDNF and to improve functional recovery of damaged neurons in preclinical models. Importantly, in an initial animal model, HER-096 has been shown to readily penetrate the blood brain barrier allowing for convenient subcutaneous dosing. Thanks to their multimodal mechanism of action, Herantis’ molecules have the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit https://www.herantis.com